FEB 27, 2019 1:30 PM PST

Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSightTM Oncology 500

Presented at: Drug Discovery 2019
Sponsored by: Illumina
Speakers

Abstract

NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events and in the future may enables the use of emerging treatments such as NTRK inhibitors. NTRK genes include numerous potential fusion partners, large intronic regions and G-C rich content, making accurate and comprehensive detection of NTRK fusions difficult to perform in the lab. Amongst the variable performance of NTRK fusion assays, NTRK detection from RNA using Hybrid-Capture NGS provides comprehensive and accurate fusion detection, agnostic of the fusion partner. TruSightTM Oncology 500 is the latest comprehensive genomic profiling assay from Illumina and enables optimal NTRK fusion detection. 

Learning Objectives:

1. Value to adopt comprehensive genomic profiling in today's oncology care.
2. How the Illumina TruSightTM Oncology 500 comprehensive genomic profiling assay enables optimal NTRK fusion detection. 


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
FEB 27, 2019 1:30 PM PST

Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSightTM Oncology 500

Presented at: Drug Discovery 2019
Sponsored by: Illumina


Show Resources
Loading Comments...
Show Resources